What is the 13F Pro Quality Score for GILD?

13F Pro ranks GILEAD SCIENCES, INC. (GILD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GILD's current score at https://13fpro.ai/company/GILD (free sign-up required for the full ranking).

Which hedge funds own the most GILD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of GILD include BlackRock,, VANGUARD CAPITAL MANAGEMENT, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/GILD as soon as new 13F filings post.

Where does 13F Pro source GILD data?

All GILEAD SCIENCES, INC. fundamentals and ownership data come directly from SEC EDGAR. GILEAD SCIENCES, INC. files with the SEC under CIK 882095. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GILD in?

GILEAD SCIENCES, INC. (GILD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives GILD's revenue?

Per GILEAD SCIENCES, INC.'s latest 10-Q filed with the SEC on 2026-08-06, the biggest revenue drivers are: HIV ($5,693M, +12% YoY); Biktarvy ($3,772M, +7% YoY); Liver Disease ($877M, +10% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/GILD.

What are GILD's largest expenses?

GILEAD SCIENCES, INC.'s latest 10-Q reports these as the largest expense items: Acquired in-process research and development ($11,183M, vs $61M a year ago); Selling, general and administrative ($1,921M, +41% YoY); Research and development ($1,764M, +18% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is GILD research updated on 13F Pro?

GILD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GILEAD SCIENCES, INC.(GILD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 882095 GILD stock profile & AI dashboard →

13F Pro Quality Score

57.4/100

Rank #1,095 of 2,961 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

45.3/100

Profitability

17.8/100

Balance Sheet

21.0/100

Earnings Quality

93.0/100

Free Cash Flow

92.1/100

Institutional Flow

80.2/100

Revenue Scale

95.1/100

Dilution Risk

32.1/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why GILD Scores 57/100

exact factor attribution · 2026-09-11

GILD's composite is driven by scale and free cash flow, held back by profitability and capital efficiency. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+6.8 pts

95th pct

Free cash flow

+6.3 pts

92th pct

Earnings quality

+4.3 pts

93th pct

Institutional flow

+1.5 pts

80th pct

Shareholder dilution

-0.9 pts

32th pct

Revenue growth

-0.9 pts

45th pct

Earnings growth

-1.9 pts

12th pct

Capital efficiency

-2.9 pts

21th pct

Profitability

-4.8 pts

18th pct

Latest change (2026-08-06): 78 → 78 · ↓ Institutional flow 55→43

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

GILD Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for GILEAD SCIENCES, INC. (GILD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GILD at 57.4/100 on a 32-signal composite quality model, placing it at rank #1,095 of 2,961 stocks — the top half of the AI-ranked universe. GILD scores in the top quartile across revenue scale (95.1), earnings quality (93.0), free cash flow (92.1). Areas of concern include profitability (17.8) and balance sheet strength (21.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 32.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), GILEAD SCIENCES, INC. reports quarterly revenue of $7.8B, net income of $-10.5B, free cash flow of $3.4B. Top institutional holders of GILD by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, FMR, based on the most recent SEC filings. GILD trades on the Nasdaq exchange and files with the SEC under CIK 882095. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GILD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GILEAD SCIENCES, INC. directly from SEC EDGAR. GILEAD SCIENCES, INC.'s 13F Pro composite quality score has ranged between 51 and 80 since 2021, currently 57.4 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about GILEAD SCIENCES, INC.

Quirks, history, and lore behind GILD — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · large-cap · listed on Nasdaq · headquartered in Northern California.
2
The Numbers
Annual revenue around $27 billion, with profit margins that most industries can only dream about — antiviral drugs are very, very good business.
3
The History
Founded in 1987, it spent years as a quiet biotech before transforming medicine in the 2010s with drugs so effective they essentially cured a previously incurable disease.
4
The Secret
Its hepatitis C franchise was once a $10-billion-a-year juggernaut — then it worked so well it nearly cured its own market out of existence.
5
The Lore
When COVID-19 hit, the world's eyes turned to its antiviral remdesivir — the first drug authorized to treat the disease in the U.S.
6
The Giveaway
The maker of Sovaldi, Harvoni, and the HIV treatment backbone Truvada — this Foster City giant essentially rewrote the rulebook on antiviral medicine.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving GILD's Business? Latest 10-Q Breakdown

✓ 29/29 datapoints verified

AI-extracted from GILEAD SCIENCES, INC.'s 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Revenue rose 10% to $7.8B, but $11.2B of acquired IPR&D charges from the Arcellx, Tubulis and Ouro deals plus a $1.75B impairment produced a $10.5B net loss.

Biggest Revenue Drivers

HIV$5,693M+12% YoY

Primarily due to higher average realized price and demand

Liver Disease$877M+10% YoY

Higher demand for Livdelzi, hepatitis B products and Hepcludex, offset by lower HCV sales

Biggest Revenue Drivers

Total revenue: $7,803M+10% YoY

HIV$5,693M+12% YoY

Primarily due to higher average realized price and demand

Within HIV

Biktarvy$3,772M+7% YoY

Higher average realized price, favorable inventory dynamics and patients switching from Genvoya

Liver Disease$877M+10% YoY

Higher demand for Livdelzi, hepatitis B products and Hepcludex, offset by lower HCV sales

Oncology$873M+3% YoY

Trodelvy growth offset by Cell Therapy decline on competitive headwinds

Within Oncology

Trodelvy$457M+26% YoY

Primarily due to higher demand

Largest Expense Items

Acquired in-process research and development$11,183Mvs $61M a year ago

$7.0B Arcellx, $3.1B Tubulis and $1.0B Ouro Medicines net of Lakefront's $860M share

Selling, general and administrative$1,921M+41% YoY

Higher HIV promotional spend and integration costs, including $332M of acquisition-related stock-based compensation

Research and development$1,764M+18% YoY

Integration expenses including $229M of stock-based compensation from the acquisitions; clinical study costs fell 3%

In-process research and development impairments$1,750Mvs $190M a year ago

Full write-off of the NSCLC IPR&D asset after discontinuing the Phase 3 EVOKE-03 Trodelvy study

Margins: Product gross margin was 79.3%, described as relatively flat versus 78.7% a year ago (+58 bps). Cost of goods sold rose 5% to $1,579M.

Watch Items from the Filing

Acquisitions consumed liquidity: cash fell to $3.2B from $7.6B, all marketable debt securities were sold, and total debt rose to $26.2B.
HHS selected Biktarvy — a $3.8B quarterly product — for Medicare Maximum Fair Price determination effective 2028.
Approximately 60% of accounts receivable relates to three wholesalers: Cardinal Health, Cencora and McKesson.
Cell Therapy sales fell 14% to $417M on lower demand reflecting ongoing competitive headwinds; Veklury fell 81% to $23M.
Product liability suits involve approximately 23,000 active plaintiffs; California Supreme Court ruled in Gilead's favor in August 2026, federal bellwether trial set for March 2027.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$7.8B

Net Income

Q2 2026

$-10.5B

Free Cash Flow

Q2 2026

$3.4B

D/E Ratio

Q2 2026

2.63

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+2.4% YoY

$29.44BFY 2025

FY22 $27.28BFY23 $27.12BFY24 $28.75BFY25 $29.44B

Net Income

+1672.9% YoY

$8.51BFY 2025

FY22 $4.59BFY23 $5.67BFY24 $480.0MFY25 $8.51B

Operating Income

+503.0% YoY

$10.02BFY 2025

FY22 $7.33BFY23 $7.61BFY24 $1.66BFY25 $10.02B

EPS (Diluted)

+1684.2% YoY

$6.78FY 2025

FY22 $3.64FY23 $4.50FY24 $0.38FY25 $6.78

Total Assets

+0.0% YoY

$59.02BFY 2025

FY22 $63.17BFY23 $62.13BFY24 $58.99BFY25 $59.02B

Total Debt

+0.7% YoY

$30.55BFY 2025

FY22 $29.77BFY23 $28.58BFY24 $30.34BFY25 $30.55B

Op. Cash Flow

-7.5% YoY

$10.02BFY 2025

FY22 $9.07BFY23 $8.01BFY24 $10.83BFY25 $10.02B

Free Cash Flow

-8.2% YoY

$9.46BFY 2025

FY22 $8.34BFY23 $7.42BFY24 $10.30BFY25 $9.46B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$29.44B +2.4%	$28.75B +6.0%	$27.12B -0.6%	$27.28B -0.1%	$27.30B +10.6%	$24.69B
Net Income	$8.51B +1672.9%	$480.0M -91.5%	$5.67B +23.4%	$4.59B -26.2%	$6.22B +4961.0%	$123.0M
Operating Income	$10.02B +503.0%	$1.66B -78.1%	$7.61B +3.8%	$7.33B -26.1%	$9.92B +143.6%	$4.07B
EPS (Diluted)	$6.78 +1684.2%	$0.38 -91.6%	$4.50 +23.6%	$3.64 -26.2%	$4.93 +4830.0%	$0.10
Total Assets	$59.02B +0.0%	$58.99B -5.0%	$62.13B -1.7%	$63.17B -7.0%	$67.95B -0.7%	$68.41B
Total Debt	$30.55B +0.7%	$30.34B +6.1%	$28.58B -4.0%	$29.77B +0.2%	$29.73B -19.5%	$36.92B
Operating Cash Flow	$10.02B -7.5%	$10.83B +35.2%	$8.01B -11.8%	$9.07B -20.3%	$11.38B +39.4%	$8.17B
Free Cash Flow	$9.46B -8.2%	$10.30B +38.9%	$7.42B -11.1%	$8.34B -22.8%	$10.80B +43.7%	$7.52B

Get alerted when GILD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GILEAD SCIENCES, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GILD

BlackRock, Inc.
$15.4B121,844,108 sh
VANGUARD CAPITAL MANAGEMENT LLC
$10.2B81,091,734 sh
FMR LLC
$8.4B66,870,816 sh
STATE STREET CORP
$7.7B61,216,552 sh
Capital World Investors
$5.2B40,988,975 sh
Invesco Ltd.
$5.0B39,819,151 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$4.5B35,316,168 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.8B30,065,642 sh
PRICE T ROWE ASSOCIATES INC /MD/
$3.8B29,996,694 sh
MORGAN STANLEY
$3.0B24,004,354 sh

Fund	Value	Shares
BlackRock, Inc.	$15.4B	121,844,108
VANGUARD CAPITAL MANAGEMENT LLC	$10.2B	81,091,734
FMR LLC	$8.4B	66,870,816
STATE STREET CORP	$7.7B	61,216,552
Capital World Investors	$5.2B	40,988,975
Invesco Ltd.	$5.0B	39,819,151
VANGUARD PORTFOLIO MANAGEMENT LLC	$4.5B	35,316,168
GEODE CAPITAL MANAGEMENT, LLC	$3.8B	30,065,642
PRICE T ROWE ASSOCIATES INC /MD/	$3.8B	29,996,694
MORGAN STANLEY	$3.0B	24,004,354

Companies Similar to GILD

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

MRK

Merck & Co., Inc.

AI score

Very similar · 51 shared holders

PeakShares LLC NORDEA INVESTMENT MANAGEMENT AB National Pension Service

PFE

PFIZER INC

AI score

Very similar · 42 shared holders

Capital World Investors PeakShares LLC National Pension Service

ABBV

AbbVie Inc.

AI score

Very similar · 49 shared holders

Capital World Investors Capital Research Global Investors Boston Partners

ABT

ABBOTT LABORATORIES

AI score

Very similar · 40 shared holders

Capital Research Global Investors National Pension Service Holocene Advisors, LP

CVS

CVS HEALTH Corp

AI score

Very similar · 47 shared holders

Capital World Investors DODGE & COX Capital Research Global Investors

BMY

BRISTOL MYERS SQUIBB CO

AI score

Very similar · 47 shared holders

NORDEA INVESTMENT MANAGEMENT AB Robeco Institutional Asset Management B.V.LSV ASSET MANAGEMENT

MDT

Medtronic plc

AI score

Very similar · 39 shared holders

Capital Research Global Investors Capital World Investors DODGE & COX

BDX

BECTON DICKINSON & CO

AI score

Very similar · 32 shared holders

Clearbridge Investments, LLC NORDEA INVESTMENT MANAGEMENT AB National Pension Service

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GILD on your watchlist

Track score changes the day GILEAD SCIENCES, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GILD a good stock to buy?

13F Pro's AI-powered analysis of GILEAD SCIENCES, INC. (GILD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GILD are available on the GILD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GILD is classified as a large company.

Which hedge funds own GILD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GILD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GILEAD SCIENCES, INC.'s investment landscape.